AC
ACUT.US Accustem Sciences Inc
- Market cap
- USD 2.09M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ACUT.US undervalued?
Graham numberThe Graham number of Accustem Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Accustem Sciences Inc fundamental analysis
No fundamental analysis for Accustem Sciences Inc yet.
Accustem Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Accustem Sciences Inc
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuSt…
Full company profileAccustem Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Accustem Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | - | - | -3.75M | -2.05M | -1.51M | -1.76M | -1.67M |
| EBITDA | - | - | -3.74M | -2.05M | -1.50M | -1.76M | -1.67M |
| Net Income | - | - | -3.75M | -2.05M | -1.51M | -1.76M | -1.48M |
| EPS | - | - | -0.33 | -0.18 | -0.12 | -0.11 | -0.09 |
| Balance Sheet | |||||||
| Total Assets | - | - | 940K | 134K | 50.9K | 1.55M | 1.61M |
| Total Liabilities | - | - | 1.08M | 2.25M | 3.36M | 4.95M | 5.72M |
| Shareholders' Equity | - | - | -140K | -2.11M | -3.31M | -3.40M | -4.12M |
| Cash & Short-term Investments | - | - | 734K | 21.5K | 5.05K | 13.9K | 12.9K |
| Cash Flow | |||||||
| Operating Cash Flow | -1.81M | -1.81M | -1.81M | -1.62M | -664K | -850K | -1.25M |
| Capital Expenditure | 11.0K | 11.0K | 11.0K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | -1.82M | -1.62M | -664K | -850K | -1.25M |
| Ratios | |||||||
| ROA | - | - | -398.7% | -1,531.5% | -2,959.8% | -113.3% | -92.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Accustem Sciences Inc dividends
Accustem Sciences Inc has not paid dividends in the last 6 fiscal years.
Who owns Accustem Sciences Inc
- Insiders 50.92%
- Institutions 0.00%
- Public & others 49.08%
- Shares outstanding 16.1M
- Free float 11.0M
Accustem Sciences Inc company profile
- Company name
- Accustem Sciences Inc
- Ticker
- ACUT.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 5 Penn Plaza, New York, NY, United States, 10001
- Website
- accustem.com
About Accustem Sciences Inc
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
Accustem Sciences Inc management
5- Mr. Gabriele Marco Antonio Cerrone M.B.A.Executive Chairman of the Board · born 1972
- Ms. Wendy E. BlosserCEO & Director · born 1966
- Mr. Jeff FenstererChief Operating Officer · born 1980
- Mr. Joe FlanaganChief Business Officer · born 1974
- Ms. Keeren ShahChief Financial Officer · born 1976